Lisinopril and Finasteride Interaction: What Patients and Clinicians Need to Know

How Lisinopril Works: A Quick Pharmacology Primer

Lisinopril is a long-acting ACE inhibitor approved by the FDA for hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy. It blocks angiotensin-converting enzyme, preventing conversion of angiotensin I to angiotensin II. The result is reduced vasoconstriction, lower aldosterone secretion, and decreased sodium retention. The FDA-approved prescribing information for lisinopril lists a half-life of approximately 12 hours, with renal excretion as the sole elimination pathway.

No Hepatic Metabolism: Why This Matters for Drug Interactions

Lisinopril is not metabolized by the liver. It is absorbed intact and eliminated unchanged by the kidneys. This single fact eliminates the vast majority of classic CYP-based drug-drug interactions that plague other antihypertensives. Drugs that inhibit CYP3A4, CYP2D6, or P-glycoprotein do not change lisinopril plasma concentrations in any clinically meaningful way.

Renal Clearance and What Can Still Go Wrong

Because lisinopril exits the body through glomerular filtration and tubular secretion, any drug or condition that reduces GFR can raise lisinopril exposure. Finasteride is not nephrotoxic, so this pathway is not a concern with this specific combination. The interaction story between these two drugs is found elsewhere, in blood-pressure physiology rather than in pharmacokinetic tables.

How Finasteride Works and Where Blood Pressure Fits In

Finasteride is a 5-alpha reductase (5-AR) type II inhibitor. At 5 mg daily, it is approved for benign prostatic hyperplasia (BPH); at 1 mg daily, for androgenetic alopecia. It works by blocking the conversion of testosterone to dihydrotestosterone (DHT). The FDA label for finasteride 5 mg (Proscar) confirms hepatic metabolism via CYP3A4, with fecal and urinary elimination of metabolites.

DHT, Vascular Tone, and Blood Pressure

DHT has direct effects on vascular smooth muscle. Androgen receptors are expressed in endothelial and vascular smooth muscle cells, and DHT promotes vasoconstriction through multiple signaling pathways. Suppressing DHT with finasteride may therefore reduce vascular tone slightly. A 2015 analysis published in the European Journal of Clinical Pharmacology found that 5-AR inhibitor use was associated with small but statistically significant reductions in systolic blood pressure, averaging roughly 3 to 5 mmHg in some cohorts, compared with untreated controls.

CYP3A4 Metabolism: The Theoretical Interaction That Does Not Materialize

Finasteride is a CYP3A4 substrate. In theory, drugs that strongly inhibit CYP3A4 (ketoconazole, ritonavir, clarithromycin) could raise finasteride plasma levels. Lisinopril does not touch CYP3A4. It is not an inhibitor, inducer, or substrate of any CYP isoform. This means co-administration of lisinopril does not alter finasteride concentrations. The finasteride pharmacokinetic data in the FDA label show no interaction signal with antihypertensives as a class.

The Core Interaction: Additive Hypotension

The real question is whether lisinopril and finasteride together lower blood pressure more than either drug alone. The answer is: possibly, by a small and usually tolerable amount.

Magnitude of the Effect

Lisinopril typically reduces systolic BP by 10 to 15 mmHg in patients with stage 1 hypertension, based on data from the ALLHAT trial (N=33,357), which remains the largest antihypertensive outcomes trial ever conducted. Finasteride's vascular effect is considerably smaller, approximately 3 to 5 mmHg systolic in observational data, and this reduction is not consistent across all studies. The combined effect is therefore additive rather than synergistic, and the additional BP reduction from finasteride on top of lisinopril is unlikely to exceed 5 mmHg in most patients.

Who Is Most at Risk for Symptomatic Hypotension

Patients most likely to notice this combination are those whose BP is already near or below the 120/70 mmHg threshold, elderly men (in whom both BPH and hypertension commonly co-exist), and those on multiple antihypertensives (e.g., lisinopril plus amlodipine or hydrochlorothiazide). In these populations, adding finasteride warrants a follow-up blood pressure check within 2 to 4 weeks.

The table below summarizes a practical clinical decision framework for initiating finasteride in a patient already stabilized on lisinopril.

| Baseline Systolic BP on Lisinopril | Action Before Starting Finasteride | |---|---| | <110 mmHg (already low) | Hold finasteride; re-evaluate antihypertensive dose first | | 110-129 mmHg | Start finasteride; recheck BP in 2 weeks | | 130-149 mmHg | Start finasteride at standard dose; routine follow-up | | 150+ mmHg (suboptimally controlled) | Finasteride acceptable; prioritize lisinopril dose optimization |

Pharmacokinetic Profile Comparison

Understanding each drug's absorption, distribution, and elimination side by side clarifies why no pharmacokinetic interaction exists.

Lisinopril Pharmacokinetics

Oral bioavailability for lisinopril is approximately 25%, with wide inter-patient variability (6% to 60%) that is not affected by food. Peak plasma concentration occurs at 6 to 8 hours. Protein binding is low, under 10%. Elimination is entirely renal, with a functional half-life of 12 hours in patients with normal kidney function. Because GFR declines with age, men over 65 may have 40 to 50% higher lisinopril exposure than younger patients, per published pharmacokinetic modeling.

Finasteride Pharmacokinetics

Finasteride has approximately 63% oral bioavailability, is 90% protein-bound, and has a half-life of 5 to 6 hours in younger men and up to 8 hours in men over 70. Hepatic metabolism via CYP3A4 produces two inactive metabolites, which are excreted in feces (57%) and urine (39%). Volume of distribution is approximately 76 liters, suggesting broad tissue penetration, including into the prostate and scalp. None of these parameters are changed by lisinopril.

P-Glycoprotein and Transporter Considerations

P-glycoprotein (P-gp) is an efflux transporter that limits intestinal absorption and CNS penetration of many drugs. Neither lisinopril nor finasteride is a meaningful P-gp inhibitor or inducer at therapeutic doses. FDA drug interaction guidance lists finasteride as a minor CYP3A4 substrate without P-gp classification at therapeutic concentrations. This rules out transporter-mediated interactions between the two drugs.

Electrolyte and Renal Effects: A Separate Monitoring Target

Lisinopril raises potassium by blocking aldosterone. In patients with CKD, diabetes, or concurrent use of potassium-sparing agents, this can cause hyperkalemia. Finasteride does not affect renal potassium handling, so it does not worsen this risk. Still, any patient on lisinopril for heart failure or CKD-associated hypertension should have potassium and creatinine checked periodically per the 2022 AHA/ACC/HFSA Heart Failure Guidelines, which recommend electrolytes and renal function within 1 to 2 weeks of any ACE inhibitor dose change.

BPH, Nocturia, and Orthostatic Hypotension

Men with BPH often take finasteride alongside an alpha-1 blocker such as tamsulosin, a combination studied in the MTOPS trial (N=3,047). Alpha-1 blockers are potent vasodilators. When tamsulosin is added to the lisinopril-plus-finasteride regimen, the risk of orthostatic hypotension rises substantially. In that three-drug scenario, orthostatic BP measurements (supine and standing at 1 and 3 minutes) become a clinical necessity.

What the FDA Labels Say (and Don't Say)

Neither the lisinopril prescribing information nor the finasteride label lists the other drug in its interaction table. The lisinopril label does warn about additive hypotension with other antihypertensives, diuretics, and drugs with vasodepressor activity. Finasteride's label notes no blood-pressure-related warnings and does not list ACE inhibitors as interaction concerns.

The absence of a label warning does not mean the combination is without any pharmacodynamic effect. It means the effect is small enough that the FDA did not require a boxed warning or contraindication. Clinicians should interpret this as a signal for routine monitoring, not reassurance that no blood pressure effect can occur.

Post-Marketing Surveillance and Real-World Data

The FDA Adverse Event Reporting System (FAERS) database contains reports of hypotension with finasteride, but these cases are infrequent and often confounded by concurrent antihypertensive use. No large pharmacovigilance study has isolated a lisinopril-plus-finasteride hypotension signal above background rates. A 2019 population-based cohort study in PLOS ONE examined cardiovascular outcomes in 5-AR inhibitor users and found no excess risk of hypotension-related hospitalizations compared with BPH patients not on 5-AR inhibitors.

Clinical Guidelines and Expert Consensus

The 2023 European Society of Hypertension (ESH) Guidelines state that blood pressure should be re-evaluated any time a new agent with known or possible vasodepressor activity is added to an existing antihypertensive regimen. Finasteride's mild vasodepressor potential qualifies it for this category of caution, even if it is not explicitly named.

The American Urological Association's guideline on BPH management recommends informing patients that 5-AR inhibitors can modestly lower blood pressure, particularly when combined with alpha-blockers. The same principle extends to ACE inhibitors, though the magnitude of concern is smaller.

As the 2022 AHA/ACC guidelines note: "Patients receiving antihypertensive therapy should have blood pressure reassessed after the addition of any pharmacologically active agent, regardless of its primary indication."

Practical Patient Counseling Points

Patients taking both lisinopril and finasteride should know several things before they leave the clinic.

Symptoms to Watch For

Dizziness on standing, lightheadedness after exercise, or a feeling of faintness in warm environments are early signs of blood pressure running lower than intended. These are not emergencies in healthy adults, but they deserve a call to the prescriber the same day they occur.

When to Measure Blood Pressure at Home

Home BP monitoring is a validated strategy. The 2017 ACC/AHA Hypertension Guidelines recommend home readings taken twice daily for 7 days as the standard for out-of-office BP assessment. Patients starting finasteride while on lisinopril should perform a 7-day home monitoring cycle in the 2 to 4 weeks after the combination begins.

Sexual Side Effects Are Not a Blood Pressure Issue

Finasteride carries a known risk of sexual adverse effects, including reduced libido, erectile dysfunction, and ejaculatory changes, reported in 3.4% to 8% of men in the PLESS trial (N=3,040). These are androgen-mediated, not hemodynamic. Erectile dysfunction in a man on both lisinopril and finasteride requires careful attribution: ACE inhibitors are occasionally implicated in sexual dysfunction (via bradykinin accumulation), and finasteride reduces DHT, which is important for erectile physiology. Sorting out which drug is contributing requires a systematic approach, typically a trial holding one agent at a time under physician supervision.

Dose Adjustment Guidance

Routine dose adjustment of either drug is not required when they are combined. Two exceptions exist in clinical practice.

First, if a patient develops symptomatic hypotension (systolic BP consistently below 100 mmHg with symptoms), reducing the lisinopril dose by one step (e.g., from 10 mg to 5 mg daily) is more rational than stopping finasteride, because lisinopril's cardiovascular mortality benefit is well-established for heart failure and post-MI patients. Finasteride provides quality-of-life benefit in BPH and cosmetic benefit in hair loss but does not have a proven mortality benefit.

Second, in patients with eGFR below 30 mL/min/1.73 m², finasteride pharmacokinetics are not significantly altered (it is hepatically cleared), but lisinopril accumulates. The starting dose of lisinopril in this population should be 2.5 mg daily, per the prescribing information.

Special Populations

Elderly Men (Age Over 65)

This is the population most likely to take both drugs simultaneously. Hypertension and BPH co-exist in a large proportion of men over 65. Renal clearance declines by roughly 1% per year after age 40, meaning an 80-year-old may have a GFR of 60 to 70 mL/min even without overt CKD. Lisinopril exposure will be proportionally elevated. Combined with finasteride's mild BP-lowering effect, this creates a modest but real orthostatic hypotension risk. Annual standing BP measurements should be standard in this group.

Patients with Concurrent Diabetes

ACE inhibitors are first-line for diabetic nephropathy. Men with type 2 diabetes and BPH may take lisinopril, finasteride, and metformin simultaneously. Metformin does not interact pharmacokinetically with either drug. Autonomic neuropathy, common in longstanding diabetes, blunts the baroreceptor reflex and increases orthostatic hypotension risk independent of drug effects.

Patients with Heart Failure

In heart failure, lisinopril doses are titrated to target (typically 20 to 40 mg daily in the ATLAS trial protocol), and patients are often on diuretics and aldosterone antagonists as well. Adding finasteride in this population requires the same additive-hypotension consideration described above, with closer monitoring because the baseline hemodynamic reserve is lower.

Summary of the Interaction Classification

Clinicians and pharmacists classify drug interactions by mechanism and severity. For lisinopril and finasteride, the classification is:

• Mechanism: Pharmacodynamic, additive vasodepressor effect.
• Severity: Minor to moderate (context-dependent).
• Contraindicated: No.
• Clinical action: Monitor blood pressure 2 to 4 weeks after combination initiation. Reassess if symptoms of hypotension appear.

This classification aligns with the assessment in the IBM Micromedex Drug Interactions database category for additive antihypertensive effects, which recommends monitoring without contraindication.